Bionano Genomics (BMV:BNGO *) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BNGO * 주식 개요

는 유전체학 연구소가 다양한 플랫폼에서 데이터를 분석하고 해석하여 인과 관계 변이를 간소화하고 간단하게 보고할 수 있는 유익한 데이터 시각화를 생성할 수 있는 유전체 분석 소프트웨어를 제공합니다.

BNGO * 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 연간 26.16% 증가할 것으로 예상됩니다.

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

최근 3개월간 주가 변동폭 심해

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

의미 있는 시가총액이 없습니다. ( MX$54M )

Bionano Genomics, Inc. 경쟁사

EZZ Life Science Holdings

ASX:EZZ

AU$81.9m

DreamCIS

KOSDAQ:A223250

₩83.7b

Inotiv

NasdaqCM:NOTV

US$43.1m

WDB coco

TSE:7079

JP¥8.3b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Bionano Genomics
과거 주가
현재 주가	US$13.00
52주 최고치	US$116.60
52주 최저치	US$12.80
베타	2.34
11개월 변경	-23.53%
3개월 변경 사항	-25.29%
1년 변경 사항	-87.74%
33년 변화	-99.03%
5년 변화	n/a
IPO 이후 변화	-99.49%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	BNGO *	MX Life Sciences	MX 마켓
7D	-7.9%	0%	0%
1Y	-87.7%	0%	0%

수익률 대 산업: BNGO * 지난 1년 동안 -5 %를 반환한 MX Life Sciences 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: BNGO * 지난 1년 동안 -1.7 %를 반환한 MX 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is BNGO *'s price volatile compared to industry and market?
BNGO * volatility
BNGO * Average Weekly Movement	14.0%
Life Sciences Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

안정적인 주가: BNGO * 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: BNGO * 의 주간 변동성( 14% )은 지난 1년 동안 안정적이었지만 여전히 MX 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2003	344	Robert Holmlin	www.bionano.com

는 유전체학 연구소가 다양한 플랫폼에서 데이터를 분석하고 해석하여 유익한 데이터 시각화를 생성하여 인과 관계 변이를 간소화하고 간단하게 보고할 수 있는 유전체 분석 소프트웨어를 제공합니다. 유전체 분석과 유전자 변이 및 기능 이해를 위한 광학 게놈 매핑을 통한 구조적 변이 분석을 위한 샘플-결과 솔루션인 Saphyr, 단일 분자 이미저인 Saphyr 기기, DNA 선형화를 위한 나노 채널 어레이를 패키징하는 소모품인 Saphyr 칩, 초고분자량 DNA 추출 및 라벨링을 위한 시약과 프로토콜을 제공하는 Bionano Prep 키트 및 DNA 라벨링 키트 등을 제공합니다. 또한 세포 유전학 및 분자 유전학을 위한 마이크로어레이 및 차세대 시퀀싱 데이터에서 유전체 변이를 분석하고 해석할 수 있는 하나의 시스템을 제공하는 Saphyr 및 Bionano 컴퓨팅 서버와 VIA 소프트웨어도 제공합니다.

Bionano Genomics, Inc. 기본 사항 요약

Bionano Genomics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
BNGO * 기본 통계
시가총액	Mex$857.22m
수익(TTM)	-Mex$4.15b
수익(TTM)	Mex$685.53m

1.3x

P/S 비율

-0.2x

P/E 비율

BNGO * 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
BNGO * 손익 계산서(TTM)
수익	US$37.47m
수익 비용	US$27.15m
총 이익	US$10.32m
기타 비용	US$237.11m
수익	-US$226.79m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-3.28
총 마진	27.54%
순이익 마진	-605.26%
부채/자본 비율	35.1%

BNGO * 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

BNGO * 주식 개요

보상

위험 분석

Bionano Genomics, Inc. 경쟁사

ASX:EZZ

AU$81.9m

KOSDAQ:A223250

₩83.7b

NasdaqCM:NOTV

US$43.1m

TSE:7079

JP¥8.3b

가격 내역 및 성능

최근 뉴스 및 업데이트

Bionano Genomics, Inc. Provides Revenue Guidance for the Second Quarter of 2024 and Reiterated Revenue Guidance for the Year 2024

First quarter 2024 earnings released: US$0.60 loss per share (vs US$1.23 loss in 1Q 2023)

Bionano Genomics, Inc., Annual General Meeting, Jun 18, 2024

Bionano Genomics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000002 million.

Bionano Genomics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000002 million.

Bionano Announces Publication Showing That Ogm Identifies Genetic Aberrations in Sarcoma Samples That May Lead to Improved Diagnosis But Were Missed by Classical Cytogenetics

Recent updates

Bionano Genomics, Inc. Provides Revenue Guidance for the Second Quarter of 2024 and Reiterated Revenue Guidance for the Year 2024

First quarter 2024 earnings released: US$0.60 loss per share (vs US$1.23 loss in 1Q 2023)

Bionano Genomics, Inc., Annual General Meeting, Jun 18, 2024

Bionano Genomics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000002 million.

Bionano Genomics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000002 million.

Bionano Announces Publication Showing That Ogm Identifies Genetic Aberrations in Sarcoma Samples That May Lead to Improved Diagnosis But Were Missed by Classical Cytogenetics

Bionano Genomics, Inc. Announces Nine Poster Presentations and Introduces New High Throughput Stratys System at American Association for Cancer Research Annual Meeting

Bionano Genomics, Inc. Announces Publication of Breast Cancer Study Showing the Number of SVs Detected with OGM May be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Bionano Genomics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Full year 2023 earnings released: US$6.81 loss per share (vs US$4.59 loss in FY 2022)

Bionano Genomics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Bionano Genomics, Inc. announced that it has received $35 million in funding

Bionano Genomics, Inc. Announces Publication of A Study That Applied Ogm to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer

Bionano Announces Full Commercial Release of the Stratys™? System for High Throughput Optical Genome Mapping

Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care in Genetic Disease Testing

Bionano Genomics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Bionano Announces Significant Upgrades to Its Bionano Solve Pipeline and Its Via™ Software for Ogm Data Analysis in Constitution Genetic Disease Research

Bionano Genomics, Inc. Reports Goodwill Impairment for the Three Months Ended September 30, 2023

Third quarter 2023 earnings released

Bionano Genomics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Bionano Genomics, Inc. announced that it expects to receive $35 million in funding

New minor risk - Market cap size

Bionano Genomics, Inc. Announces the Publication of Study Detailing the Challenges Associated with the Detection and Interpretation of Causal Variants in Mendelian Disease

Bionano Genomics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Bionano Genomics, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$1.24 loss per share (vs US$1.13 loss in 2Q 2022)

Bionano Genomics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Bionano Genomics, Inc. Announces the Stratys System for OGM and VIA™? Software for Hematologic Malignancies

Bionano Genomics, Inc.(NasdaqCM:BNGO) dropped from Russell Small Cap Comp Value Index

Bionano Genomics, Inc. Announces Peer-Reviewed Publication on the Utility of Combining Ogm and A 523-Gene Ngs Panel for Standard Evaluation of Myeloid Cancers

Independent Director recently bought Mex$862k worth of stock

Bionano Announces Commercial Release of New Kits for Its Ionic System Featuring New Chemistry for Nucleic Acid Extraction from Ffpe and Tumor Tissue

Bionano Genomics Receives Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with Minimum Bid Price Requirement

Chief Financial Officer recently bought Mex$589k worth of stock

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.10 loss in 1Q 2022)

Bionano Genomics, Inc. to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.26 loss in FY 2021)

Bionano Genomics, Inc. Launches Next-Generation Versions of Its Reagent Kits and Chip Consumable, Along with Updates to Its Instrument Control and Bionano Access Software for the Optical Genome Mapping Workflow

Bionano Genomics, Inc. Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal Testing

Bionano Genomics, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Bionano Genomics, Inc. Announces Publication of Study Utilizing Optical Genome Mapping

Bionano Genomics, Inc. Announces Resignation of Richard Shippy as Chief Business Officer

Bionano Genomics, Inc. Appoints Donna Polizio as Global Head of Market Access

Bionano Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.074 loss in 3Q 2021)

Bionano Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Bionano Genomics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Hamilton and Bionano Genomics, Inc. Announce Commercial Availability of World's First Ultra High Molecular Weight DNA Extraction Automation Solution for OGM

Bionano Genomics Announces Publication of Study from Sorbonne Université Showing That WGS Identified Only 63% of Structural Variations That OGM Detected in Liver Cancer

Bionano Genomics Announces Launch of CLIA-Certified Bionano Laboratories

Bionano Genomics, Inc. Announces Publication of Study Using OGM for Detection of Balanced Chromosomal Rearrangements Found in Recurrent Pregnancy Loss

Bionano Genomics Announces Publication of Study Demonstrating Utility of OGM as Part of Comprehensive Workflow for Quality Evaluation of Human Induced Pluripotent Stem Cells

Bionano Genomics, Inc. Announces the First Publication Using OGM to Analyze Impact of Chromothripsis and TP53 Abnormalities on Chronic Lymphocytic Leukemia (CLL) Patients with High Genomic Complexity

Bionano Genomics Announces First Publication Using Ogm for Detection of Repeat Expansions in Canvas and Adult-Onset Ataxia

Bionano Genomics, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.067 loss in 2Q 2021)

Bionano Genomics, Inc. Announces Publication of Research Study in Myelodysplastic Syndrome

Bionano Genomics, Inc. Announces Publication of a New Study Using OGM to Investigate Chromosome Instability During Culture of Induced Pluripotent Stem Cells

Bionano Genomics, Inc. Announces Publication of a New Study Using OGM to Investigate Inversions that May Lead to Genetic Disorders